TF and COVID-19: COVID-19 patients show many of the pathophysiological processes that are associated with the cellular release of EVs, including endothelial injury, platelet hyper-reactivity, TF-mediated procoagulant activity, and increased thrombin generation (Iba et al., 2020b; Spiezia et al., 2020; Campello et al., 2021a; Lippi et al., 2021).